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Abstract
Background: Overgrowth syndromes represent clinically and genetically heterogeneous conditions characterized
by a wide spectrum of malformations, tall stature, intellectual disability and/or macrocephaly.
Results: In a cohort of four clinically characterized patients with overgrowth syndrome without known causative
gene mutation, we performed an Illumina SNP-array analysis to identify the pathogenic copy number variations.
We identified two rare copy number variations harboring overgrowth syndrome related genes. Patient 1 was
Malan syndrome with a 1.4 Mb 19p13.2-13.13 microdeletion including NFIX, and Patient 2 was identified as Sotos
syndrome with a 1.6 Mb 5q35.2 microdeletion encompassing NSD1.
Conclusions: We identified two patients associated with Manlan syndrome and Sotos syndrome respectively.
We also discuss the use of the microarrays-based candidate gene strategy in Mendelian disease-gene identification.
Keywords: Deletion 19p13.2-13.13, Deletion 5q35.2, NSD1, SNP-array, Epigenetic diseases, Microarrays-based candidate
gene strategy
Background
Overgrowth with multiple birth defects is useful pheno-
typic sign in diagnostic categorization of congenital
diseases. Overgrowth syndromes (OGSs) are a group of
heterogeneous disorders including Sotos syndrome
(SOTOS1, OMIM#117550), Beckwith-Wiedemann syn-
drome (BWS; OMIM#130650), Simpson-Golabi-Behmel
syndrome (SGBS1, OMIM#312870), Proteus syndrome
(PS, OMIM#176920), Bannayan-Riley-Ruvalcaba syndrome
(BRRS, OMIM#153480) and Weaver Syndrome (WVS,
OMIM #277590) [1]. Recently the molecular causes of
several OGSs have been revealed [2]. Despite these
advances, the underlying genetic mechanisms for 20–40 %
of overgrowth individuals remain unknown [2].
Malan syndrome, also named as Sotos-like syndrome
or Sotos syndrome 2 (SOTOS2, OMIM#614753), is a
recently introduced clinical condition characterized by
tall stature, intellectual disability and/or macrocephaly
[2–4]. This syndrome has been associated with the NFIX
gene on chromosomal locus 19p13.2. NFIX encodes the
nuclear factor I X (CCAAT-binding transcription factor)
protein [5]. It has been suggested that either a nonsense
mutation in the NFIX gene or microdeletion encompassing
NFIX underlies this syndrome [2, 6].
As part of a larger study on the identification of patho-
genic copy number variations in children with birth de-
fects, four overgrowth children carrying multiple birth
defects with undetermined genetic reasons were en-
rolled in this study. High-resolution SNP-array analysis
(Illumina, San Diego, CA, USA) was performed to
analyze the genomes of these patients. Here, we present
two patients with overgrowth syndromes, Patient 1 was
diagnosed as Malan syndrome with a 1.4 Mb deletion
in chromosomal region 19p13.2-13.13, and Patient 2
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This male patient was two-year and seven-month old at
the time of genetic evaluation. He was the second child
of a healthy unrelated couple. Family history of birth
defects or genetic disorders was denied. He was born at
39 weeks of gestation by normal delivery. His birth
weight was 4000 g (75-90th centile) with a birth length
of 51 cm (50th centile) and a head circumference of
37 cm (75–90th centile). Due to respiratory failure, the
patient was treated with intubation and artificial respira-
tion and admitted to the neonatal intensive care unit
(NICU). At six months, he attended to the Second Xian-
gya Hospital because of development delay. At this time,
he weighed 8000 g (75–90th centile) with a length of
72 cm (50th centile) and a head circumference of 43 cm
(75–90th centile). Mildly reduced volume of the white
matter, and the thin corpus callosum were revealed by
brain MRI. Electroencephalogram (EEG) showed no
definite abnormality. At present, his length is 79 cm
(50th centile), weight 12 kg (50th centile) and OFC
48.6 cm (75–90th centile), suggesting that his head is
relatively large compared with his stature. He showed
frontal bossing, high forehead, deep-set eyes, sparse eye-
brows, a flat nasal bridge, low-set ears, high-arched palate,
bilateral strabismus and pectus excavatum (Fig. 1). He
could not sit up and walk by himself. Also he could not
speak any meaningful words. His psychomotor develop-
ment was evaluated by the GESELL Developmental
Diagnosis Scale (GDDS) and the developmental quotient
(DQ) was determined to be 19. Neurological examination
revealed generalized hypotonia and reduced deep tendon
reflexes. Peripheral nerve conduction velocities showed no
abnormalities. Conventional G-banding analyses showed
no abnormalities.
Patient 2
The patient was referred to the genetic service at the age
of three years with intellectual disability, macrocephaly and
congenital heart defect (patent ductus arteriosus, PDA).
This girl was born to non-consanguineous, healthy parents.
At her birth, her mother and father were both at 36 years
old. She was born by cesarean at 39 weeks plus 4 days with
a birth weight 3,780 g (70–90th centile); birth length of
52 cm (90th centile) and a head circumstance of 36.8 cm.
Frontal bossing, high forehead, deep-set eyes and con-
genital heart disease were observed. Eye anomalies,
heterochromia and congenital microphthalmia were
also observed. Conventional G-banding analyses showed
no abnormalities.
Patient 3
Patient 3 attended to our hospital due to congenital
heart disease. Family history was absent. He was six-
year old and had several distinct phenotypes, i.e. ASD
(atrial septal defect), tall stature and behavior problems
(self-hugging and frequent temper outbursts).
Patient 4
This patient was a five-year old boy. He was the second
child of unrelated parents without obvious family history
Fig. 1 Clinical photographs of the probands. a: Patient 1 with Malan syndrome shows frontal bossing, high forehead, deep-set eyes, sparse eyebrows,
a flat nasal bridge, low-set ears, high-arched palate, and bilateral strabismus. b, c: lateral view of the Patient 2 with Sotos syndrome. Frontal bossing,
high forehead, deep-set eyes, heterochromia and congenital microphthalmia were observed
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of inherited disease. Congenital heart defect (PDA),
frontal bossing and high forehead, macrocephaly, big
toe and also behavior problems (impulsiveness, frequent
temper tantrums and outbursts) were observed.
Methods
The Review Board of the Second Xiangya Hospital of
the Central South University approved this study. All
subjects consented to this study.
Chromosome analysis was performed on peripheral
blood of the patient and the parents by conventional
G-banded techniques (550-band resolution). 5 ml peri-
pheral blood was collected for each individual. All samples
were subjected to lymphocyte culture according to
standard cytogenetic protocol.
The genomic DNA was prepared from peripheral
blood of the patient and the parents. Genomic DNA was
prepared using a DNeasy Blood & Tissue Kit (Qiagen,
Valencia, CA) on the QIAcube automated DNA extrac-
tion robot (Qiagen, Hiden, Germany).
Genomic DNA samples of the patient and parents
were adjusted to a final concentration of 50 ng/μl. The
HumanOmni1-Quad Chip (Illumina Inc., San Diego, USA)
and the Illumina BeadScan genotyping system (Beadstation
Scanner) were employed to obtain the signal intensities of
SNP probes [7, 8]. Human Omni1-Quad Beadchip con-
tains over 1.1 million loci across the human genome. The
GenomeStudio V2011 software was used to analyze the
genotypes (human genome build 37/Hg19 for analysis)
and evaluate the experimental quality. The call rates of the
samples are greater than 99.5 %.
Results
Conventional G-banding analyses showed no abnormal-
ities in four children with overgrowth syndromes. To
identify the patients' genetic lesions, we employed SNP-
array system (HumanOmni1-Quad Chip) to analyze the
possibility of pathogenic copy number variations (pCNVs).
A de novo 1.4 Mb deletion ranging from 19p13.2 to
19p13.13 (chr19: 12,157,839-13,518,462/hg19) was identi-
fied in Patient 1 with unique clinical phenotypes i.e.
macrocephaly, overgrowth and intellectual disability. This
chromosome region is gene-rich and contains several
OMIM genes NFIX, CACNA1A and CALR (Fig. 2).
Consistent with previous reports that deletions of
19p13.2 are associated with overgrowth and other ab-
normalities, this patient got a clinically diagnosis as
Malan syndrome (19p13.2 microdeletion syndrome). In
addition, a de novo 1.6 Mb deletion on chromosomal
locus 5q35.2 encompassing NSD1 (chr5:175,548,190-
177,145,695/hg19) was revealed in Patient 2 with Sotos
syndrome. SNP-array analysis showed no pathogenic
deletions or duplications in Patient 3 and Patient 4,
hence these two patients remain undiagnosed.
Discussion
Overgrowth syndromes are a group of conditions with
heterogeneity and share several cardinal clinical features,
i.e., overgrowth, intellectual disability and/or macrocephaly.
The complexity of phenotypic features makes the differen-
tial diagnoses of overgrowth syndromes difficult. Recent
advances in genetic studies have facilitated the molecular
delineation of overgrowth syndromes. As a result, several
overgrowth syndromes have been genetically elucidated in
last decade. In this study, we report two patients with dis-
tinct overgrowth syndromes, Malan syndrome (19p13.2
deletion of NFIX) and Sotos Syndrome (5q35.2 deletion
of NSD1).
In 2010, Malan et al. combined chromosomal microar-
rays and candidate gene approaches and successfully dis-
covered nonsense mutations or microdeletion of NFIX in
patients with Sotos-like overgrowth syndrome [6]. Muta-
tions in NFIX had been linked to a known clinical condi-
tion, Marshall-Smith syndrome (MSS, OMIM#602535)[9].
It is suggested that different types of NFIX variants under-
lie distinct clinical phenotypes [6]. Specifically, frameshift
and splice mutations in NFIX resulted in Marshall-Smith
syndrome (MSS) while NFIX deletions and nonsense mu-
tations cause a Sotos-like overgrowth syndrome. This
phenomenon that distinct mutations result in strikingly
different phenotypes has also been observed in other syn-
dromes i.e. PTEN mutations cause Cowden syndrome
(CS) and Bannayan-Riley-Ruvalcaba syndrome (BRRS)
and Proteus syndrome (PS)[10], while FBN1 underlies
Marfan syndrome, Weill-Marchesani syndrome (WMS)
and acromicric dysplasia.[11, 12]. Subsequently, several re-
ports confirmed NFIX mutations in patients with Sotos
syndrome-like features resembling the patients previously
reported by Malan et al. [2, 3, 13, 14]. In 2015, Klaassens
et al., reported six additional patients with point mutation
or deletion of NFIX [2]. Literature review of patients
with 19p13.2-19p13.13 deletions showed similar clinical
features [15–20]. Finally this medical condition was col-
lectively grouped as Malan syndrome (19p13.2 deletion
syndrome).
Common and prominent features are shared by different
types of overgrowth syndromes, which imply that these
syndromes might share similar molecular mechanisms.
Since the two overgrowth disease-related genes, NFIX and
NSD1, are both transcription factor, we suspect that they
might be involved in similar molecular processes. The
transcription factor nuclear factor I X plays a pivotal role
during the development of brain and skeleton [5]. The
Nfix(-/-) mice have retarded growth and most would die
after postnatal day 21 (P21) in addition to malformations
in brain ventricles and the corpus callosum [5]. NSD1 en-
codes a protein containing a SET domain, four plant
homeodomain (PHD) finger regions and a proline-rich re-
gion. The SET Domain of NSD1 protein has intrinsic
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Fig. 2 Human Omni1-Quad SNP-array result of the 19p13.2-p13.13 in Patient 1 with Malan syndrome. SNP-based array shows a de novo 1.4 Mb
deletion (chr19: 12,157,839-13,518,462/hg19). Log R ratio and B allele frequencies are showed in upper panel; the lower panel shows genes in the
deleted region
Table 1 Mendelian causative genes identified by the microarrays-based candidate gene strategy
Gene Locus Size (kb) Syndrome/phenotype Year Reference
RAI1 17p11.2 4000 Smith–Magenis syndrome 2003 Nat Genet.2003; 33:466-8.
CHD7 8q12 2300 CHARGE syndrome 2004 Nat Genet. 2004; 36:955-7.
EHMT1 9q34 1200 9q34 deletion syndrome 2005 J Med Genet. 2005; 42:299-306.
MECP2 Xq28 400–800 Intellectual Disability 2005 Am J Hum Genet. 2005; 77:442-53.
MAPT 17q21.31 600 17q21.31 microdeletion syndrome 2006 Nat Genet. 2006; 38:999-1001.
CHRNA7 15q13.3 1500 15q13.3 microdeletion syndrome 2008 Nat Genet. 2008; 40:322-8.
MBD5 2q23.1 200–4000 2q23.1 microdeletion syndrome 2010 Eur J Hum Genet. 2010; 18: 436-441.
NFIX 19p13.2 100–200 Sotos-like syndrome 2010 Am J Hum Genet. 2010; 87:189-98.
SHANK3 22q13.3 100–9000 Phelan-McDermid Syndrome 2011 Nature. 2011; 472: 437-42.
KANSL1 17q21.31 68 17q21.31 microdeletion syndrome 2012 Nat Genet. 2012; 44:639-41.
ARIDIB 6q25 2500 Intellectual Disability 2012 Am J Hum Genet. 2012; 90:565-72
KCTD13 16p11.2 600 Intellectual Disability 2012 Nature. 2012; 485:363-7.
TGFB2 1q41 6500 Thoracic aortic aneurysm 2012 Nat Genet. 2012; 44:922-7.
KDM6A Xp11.3 45–816 Kabuki syndrome 2012 Am J Hum Genet. 2012; 90:119-24.
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histone methyltransferase activity [21]. Based on these
observations, Sotos syndrome and Sotos-like over-
growth syndrome have been suggested to be epigenetic
diseases caused by loss-of-function defects of epigenetic
readers/writers that modify the H3K36 histone mark
[22]. Consistent with this idea, mutations in the DNA
methyltransferase gene DNMT3A, SETD2 and EZH2
have also been shown to cause overgrowth syndromes
[22–24]. Most recent NFIX function studies focus on its
role in the brain malformations, whether NFIX is involved
in epigenetic regulation remains to be elucidated [25, 26].
The discovery of NFIX as a causal gene for Malan
syndrome also provides a success example for the
microarrays-based candidate gene strategy in the iden-
tification of Mendelian disease-genes. Various mapping
approaches rely upon karyotyping, linkage analysis,
homozygosity mapping, GWAS and the recently intro-
duced chromosomal microarrays (copy number vari-
ation analysis) and WES/WGS (whole exome/genome
sequencing) [27]. An overview of literatures suggests that
13 disease-causing genes have been successfully identified
by microarrays-based approaches including array CGH
and SNP-array (Table 1). The disease gene number is rela-
tively small but shows great growing potential. More
importantly, with the accumulated copy number vari-
ation database, microarrays-based candidate gene strategy
would be more productive in combination with exome
sequencing data (Next Generation Sequencing, NGS).
Both of our patients have eye problems. Patient 1 has
strabismus which is typical findings in patients with
Malan syndrome. Patinet 2 has congenital microphthal-
mia and heterochromia. The latter two symptoms are
not commonly reported in Sotos syndrome. In addition,
Patient 1 with Malan syndrome shows no heart defects,
while Patient 2 has congenital heart disease that mostly
associated with Sotos syndrome. Whether the cardiac
defect of our Sotos syndrome patient is related to other de-
leted genes in this 5q35.2 deletion remains to be resolved.
Conclusion
In conclusion, we report two patients with overgrowth
syndrome. Patient 1 is diagnosed as Malan syndrome with
a 1.4 Mb 19p13.2-13.13 microdeletion including NFIX,
while Patient 2 has Sotos syndrome with a 1.6 Mb 5q35.2
microdeletion encompassing NSD1. Our study contributes
to the diagnosis and treatment of these diseases.
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